ArticleJournal of cachexia, sarcopenia and muscle2025
Muscle-Specific Strength Better Predicts Physical Performance Decline Than Conventional Metrics: The I-Lan Longitudinal Aging Study.
Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Associations of upper- and lower-limb muscle health components-muscle mass, absolute strength, and muscle-specific strength-with gait speed in community-dwelling older adults.European geriatric medicine · 2026Article
- Identifying Individuals at Risk of Functional Decline Despite Preserved Muscle Mass: Insights from Appendicular Skeletal Muscle Mass and Handgrip Strength Discordance.Journal of clinical medicine · 2026Article
- Comment on 'Muscle-Specific Strength Better Predicts Physical Performance Decline Than Conventional Metrics: The I-Lan Longitudinal Aging Study' by Chien et al.Journal of cachexia, sarcopenia and muscle · 2026Article
- Comment on 'Muscle-Specific Strength Better Predicts Physical Performance Decline Than Conventional Metrics: The I-Lan Longitudinal Aging Study' by Chien et al.-The Authors Reply.Journal of cachexia, sarcopenia and muscle · 2026Article
- Muscle-Specific Strength Better Predicts Physical Performance Decline Than Conventional Metrics: The I-Lan Longitudinal Aging Study.Journal of cachexia, sarcopenia and muscle · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMuscle-specific strength (MSS), defined as grip strength normalized to arm muscle mass, may better reflect muscle efficiency than grip strength. Despite its potential utility in diagnosing sarcopenia, longitudinal studies evaluating MSS as a predictor of sarcopenia-related outcomes remain limited. This study investigated the associations of MSS with physical performance deterioration and biomarker profiles in community-dwelling older adults, compared it with conventional measures, determined whether MSS-defined sarcopenia offers superior predictive utility versus traditional diagnostic criteria and examined associations with key cardiometabolic and inflammatory biomarkers.
methodsThis prospective cohort study included 1609 participants (mean age 64.5 ± 6.7 years; 50.5% male) from the I-Lan Longitudinal Aging Study. MSS was calculated by dividing handgrip strength by dominant arm muscle mass. Participants were categorized into low and normal MSS groups using age-sex-specific cutoffs based on quintiles. Physical function was assessed using the five-time chair stand test, with impaired physical performance (PPI) defined as taking ≥ 12 s. Logistic regression models examined the associations between MSS and PPI, adjusted for demographics, comorbidities, cognitive function and skeletal muscle index. Biomarker profiles, including metabolic, inflammatory and hormonal parameters, were compared across MSS groups.
resultsLow MSS was found in 19.9% of participants. Those with low MSS had significantly higher muscle mass (skeletal muscle index, 7.7 ± 1.2 vs. 7.1 ± 1.2 kg/m
conclusionsLow MSS independently predicts physical performance deterioration and associates with adverse metabolic and inflammatory biomarker profiles in older adults. MSS may better indicate muscle health than traditional metrics, supporting its inclusion in sarcopenia assessment frameworks as recommended by recent consensus guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.